<DOC>
	<DOCNO>NCT01422616</DOCNO>
	<brief_summary>ENCHANTED independent , investigator initiate , international collaborative , quasi-factorial randomise control trial involve package 2 link comparative randomised treatment arm , aim address 4 key question patient eligible thrombolysis acute phase ischaemic stroke . ( 1 ) Does low-dose ( 0.6 mg/kg ) intravenous ( i.v . ) recombinant tissue plasminogen activator ( rtPA ) provide equivalent benefit compare standard-dose ( 0.9 mg/kg ) rtPA ? ( 2 ) Does intensive blood pressure ( BP ) lowering ( 130-140 mmHg systolic target ) improve outcome compare current guideline recommend level BP control ( 180 mmHg systolic target ) ? ( 3 ) Does low-dose ( 0.6 mg/kg ) intravenous ( i.v . ) recombinant tissue plasminogen activator ( rtPA ) reduce risk symptomatic intracerebral haemorrhage ( sICH ) ? ( 4 ) Does addition intensive BP lower thrombolysis rtPA reduce risk intracerebral haemorrhage ( ICH ) ? The rtPA dose arm study address question ( 1 ) ( 3 ) conclude publication result May 2016 . The BP intensity arm study ongoing .</brief_summary>
	<brief_title>Enhanced Control Hypertension Thrombolysis Stroke Study ( ENCHANTED )</brief_title>
	<detailed_description>This study international , multicentre , prospective , fixed-time point ( optional ) randomisation two arm ( [ A ] 'dose rtPA ' [ B ] 'level BP control ' ) , open , blind endpoint ( PROBE ) , control trial involve 4700 patient ( 3310 rtPA arm { recruitment complete August 2015 } 2304 BP arm 939 overlap ) acute ischaemic stroke recruit 100+ Clinical Centres Australia , Asia , Europe South America .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Phentolamine</mesh_term>
	<mesh_term>Labetalol</mesh_term>
	<mesh_term>Urapidil</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Nicardipine</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Esmolol</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Adult ( age ≥18 year ) A clinical diagnosis acute ischaemic stroke confirm brain imaging Able receive treatment within 4.5 hour definite time onset symptom Have systolic BP ≤185 mmHg Provide inform consent ( via appropriate proxy , accord local requirement ) Specific criterion arm [ A ] lowdose v standarddose rtPA ( Recruitment complete August 2015 . ) : Able receive either lowdose standarddose rtPA Specific criterion arm [ B ] intensive BP lower vs guideline recommend BP control Patient receive thrombolysis treatment rtPA , either randomise dose within trial physician decide dose rtPA outside trial Sustained elevate systolic BP level , define 2 reading ≥ 150 mmHg Able commence intensive BP lowering treatment within 6 hour stroke onset Able receive either immediate intensive BP lower conservative BP management Unlikely potentially benefit therapy ( e.g . advanced dementia ) , high likelihood death within 24 hour stroke onset . Other medical illness interfere outcome assessment followup [ know significant prestroke disability ( mRS score 25 ) ] . Specific contraindication rtPA ( Actilyse ) blood pressure agent use . Participation another clinical trial involve evaluation pharmacological agent . Need follow concomitant medication , include phosphodiesterase inhibitor monoamine oxidase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ischemic stroke</keyword>
	<keyword>High blood pressure</keyword>
	<keyword>Thrombolysis</keyword>
	<keyword>Antihypertensive drug</keyword>
	<keyword>Disability</keyword>
	<keyword>Clinical trial</keyword>
</DOC>